Terns Pharmaceuticals (TERN)

• Market cap: $633M
• 1 day: -2.82%
• 5 days: 0.14%
• 1 month: 10.72%
• 3 months: 83.97%
• 6 months: 97.54%
• Year to date: 27.51%
• 1 year: -23.97%
• 5 years: -60.69%
• 10 years: -60.69%
• Sector: Healthcare
• Industry: Biotechnology

About: Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.

Employees: 59

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

128% more call options, than puts

Call options by funds: $910K | Put options by funds: $399K

60% more repeat investments, than reductions

Existing positions increased: 48 | Existing positions reduced: 30

35% more capital invested

Capital invested by funds: $229M [Q1] → $310M (+$80.6M) [Q2]

0% more funds holding in top 10

Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]

0.02% less ownership

Funds ownership: 95.18% [Q1] → 95.16% (-0.02%) [Q2]

7% less funds holding

Funds holding: 137 [Q1] → 128 (-9) [Q2]

28% less first-time investments, than exits

New positions opened: 23 | Existing positions closed: 32

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $7.44
• Avg. target: $7.44
• High target: $7.44

1 analyst rating

• positive: 0 0%
• neutral: 1 100%
• negative: 0 0%

HC Wainwright & Co. Andrew S. Fein

$7.44

Neutral Assumed

4 Sep 2025